Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 10/20 | 0.63 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | TEK | Q02763 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PRKCH | P24723 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312056 | 0.90 | IGF1R (0.60) | IGF1RKDRCDK2EGFRINSR | |
| SCHEMBL6312611 | 0.88 | KDR (0.52) | IGF1RKDRCDK2EGFRINSR | |
| SCHEMBL6312589 | 0.88 | IGF1R (0.59) | IGF1RKDRCDK2EGFRINSR | |
| SCHEMBL6312590 | 0.87 | IGF1R (0.58) | IGF1RKDRCDK2EGFRINSR | |
| SCHEMBL6320602 | 0.87 | KDR (0.51) | IGF1RKDRCDK2EGFRINSR | |
| SCHEMBL6318900 | 0.86 | IGF1R (0.58) | IGF1RKDREGFRAURKAPOLB | |
| SCHEMBL6319833 | 0.85 | LRRK2 (0.46) | IGF1RKDRCDK2EGFRINSR | |
| SCHEMBL6319664 | 0.84 | IGF1R (0.53) | IGF1RKDRCDK2EGFRINSR | |
| SCHEMBL6314422 | 0.83 | IGF1R (0.60) | IGF1RKDRCDK2EGFRAURKA | |
| SCHEMBL6312806 | 0.83 | IGF1R (0.47) | IGF1RKDRCDK2EGFRINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| US-7981633-B2 | measuring the autophosphorylation of one or more tyrosine kinases in presence of a kinase inhibitor compared to the absence of said kinase inhibitor; immuno assay for the detection of autophosphorylation of up to 100 different tyrosine kinases in one cavity | MERCK PATENT GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20080206800-A1 | Method for Measuring Tyrosine Kinase Phosphorylation | MERCK PATENT GESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20060193772-A1 | Drugs for treating cancer | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CANCER CENTER (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1671647-A1 | MEDICAMENT FOR TREATING CANCER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | IGF1R 4054/4885KDR 2148/4885CDK2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.